Luis Herrera Jiménez

Dr. Luis Herrera Jiménez

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2026 in Psychiatry International
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
RGRicardo Millán González
Ricardo Millán González
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.

13 March 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.

29 May 2026 in Crónicas científicas
Verified
Journal Article
Closed access
LJLuis Herrera Jiménez
Luis Herrera Jiménez
LALuis Andrés Núñez Alpízar
Luis Andrés Núñez Alpízar
FOFabricio López Ortega
Fabricio López Ortega
FMFreddy Arias Mora
Freddy Arias Mora
Este trabajo analiza la investigación biomédica realizada entre 1940 y 1975 en pacientes con esquizofrenia institucionalizados en hospitales psiquiátricos de Estados Unidos, partiendo de la hipótesis de que la ausencia de protocolos éticos estandarizados permitió su utilización sistemática en estudios experimentales, lo que finalmente condujo a la creación de mecanismos regulatorios como las Institutional Review Boards (IRB). Se discute cómo el contexto histórico de la psiquiatría asilar, la percepción de los pacientes como “material clínico disponible” y la falta de derechos civiles facilitaron la realización de experimentos farmacológicos e intervenciones invasivas (como la administración de neurolépticos, LSD, lobotomía y terapia electroconvulsiva) frecuentemente sin consentimiento informado ni supervisión ética externa. La revisión de literatura y fuentes históricas evidencia que, aunque estos estudios contribuyeron al desarrollo de la psicofarmacología y la transformación de la psiquiatría moderna, lo hicieron a costa de graves violaciones a los derechos humanos y la dignidad de los pacientes. Como resultado, las denuncias y cuestionamientos éticos derivados de estas prácticas impulsaron la creación de marcos regulatorios y la implementación obligatoria de las IRB, estableciendo la necesidad de supervisión ética, consentimiento informado genuino y protección de poblaciones vulnerables en la investigación biomédica contemporánea.

6 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JMJeaustin Arón Mora
Jeaustin Arón Mora
KCKevin Cruz-Mora
Kevin Cruz-Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.

11 August 2026 in Psychiatric Research and Clinical Practice
Verified
Journal Article
Open access
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LJLuis Herrera Jiménez
Luis Herrera Jiménez
SSSofía Suárez‐Sánchez
Sofía Suárez‐Sánchez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JMJeaustin Arón Mora
Jeaustin Arón Mora
RGRicardo Millán González
Ricardo Millán González
Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.

3 October 2026 in Psychoactives
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
LJLuis Herrera Jiménez
Luis Herrera Jiménez
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JGJosé Andrés Castro Gamboa
José Andrés Castro Gamboa
KCKevin Cruz-Mora
Kevin Cruz-Mora
RGRicardo Millán González
Ricardo Millán González
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.